CG Oncology's Phase 3 trial of cretostimogene for BCG-unresponsive high-risk NMIBC achieved a 75.2% complete response rate.
CG Oncology's Phase 3 trial of cretostimogene for high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCG treatment showed a 75.2% complete response rate over 12 months. The FDA granted Fast Track and Breakthrough Therapy Designations for the treatment of BCG-unresponsive NMIBC. The study demonstrated sustained, durable responses in patients.
May 03, 2024
4 Articles